A Phase I, Randomized, Double-masked, 3-period Cross-over Clinical Study to Compare the Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops to Those of Preservative-free Tafluprost 0.0015% and Timolol 0.5% Eye Drops in Healthy Volunteers
Latest Information Update: 29 Sep 2015
At a glance
- Drugs Tafluprost/timolol (Primary) ; Tafluprost; Timolol
- Indications Glaucoma; Ocular hypertension
- Focus Pharmacokinetics
- Sponsors Santen Oy
- 29 Sep 2015 New trial record
- 21 Sep 2015 Results published in the Clinical Pharmacokinetics.